The Grant or Nothing: Why Universities Still Don't Know How to Value a Breakthrough

A materials scientist at a technical university in the Netherlands recently licensed a polymer coating to a medical device manufacturer. The deal was worth several million euros to the institution, generated two spinout jobs, and is expected to reduce infection rates in surgical implants within three years. When her department reviewed her performance that same year, the primary question on the table was whether her publication output had kept pace with her peers. The licensing deal was noted. It was not weighted.

Her experience is not unusual. Across research universities in Europe and North America, a stubborn institutional logic persists: innovation and commercialisation — the translation of scientific work into products, companies, and real-world applications — remains systematically undervalued relative to the grant-and-publication cycle. Understanding why requires going back to the moment universities decided what they were for.

· · ·

The roots of the problem lie in the post-war settlement between governments and universities. The Vannevar Bush report of 1945, Science — The Endless Frontier, articulated an influential doctrine: fundamental research, conducted freely within universities and funded by public grants, would generate the knowledge base from which applied innovation would eventually flow. The model was elegant and, for several decades, largely accurate. It also encoded a hierarchy: basic research was noble; commercial application was downstream, secondary, almost slightly suspect.

Universities organised themselves accordingly. Promotion and tenure committees were structured around peer-reviewed publications and grant income — the two outputs most legible within the academic value system. Technology transfer offices existed, but they sat at the margins of institutional culture, operating more as legal clearinghouses for IP than as genuine partners in recognising or rewarding the researchers who generated it.

The Bayh-Dole Act of 1980 in the United States, and similar legislation across Europe through the 1990s and 2000s, gave universities ownership of publicly funded inventions and encouraged commercialisation. This was intended to accelerate the journey from lab to market. What it did not do was change the internal reward structures that determined whose career advanced and whose did not. Technology transfer became institutionally encouraged and personally unrewarded — a paradox that persists to this day.

· · ·

How it plays out in practice is corrosive in specific ways. A researcher who spends two years developing a diagnostic tool with clinical partners has invested time that does not appear on a publication list. The conversations with industry, the proof-of-concept iterations, the investor meetings required to take the work forward — none of these produce the currency that hiring committees and grant panels recognise. The researcher has, from the institution's perspective, been less productive. The fact that her work may reach a million patients is, under most evaluation frameworks, largely beside the point.

The distortion affects not only individual careers but institutional strategy. Researchers learn, over time, what their universities actually reward. Rational actors respond by directing effort toward grant applications and journal submissions, even when a different path — licensing, industry partnership, spinout formation — would deliver greater societal value. The pipeline from discovery to application narrows not because researchers lack ambition, but because ambition has been trained to point in only one direction.

There is also a visibility problem that precedes any question of institutional reward. Before a university can recognise the value of a researcher's commercialisable work, that work has to be legible — to technology transfer officers, to institutional leadership, to potential investors, and ultimately to the external world that might fund its development. Most researchers have no training in making this case. They can write a methods section with precision and defend a hypothesis before the most sceptical peer reviewer. They cannot, and should not be expected to, construct a narrative that translates years of bench work into the language of market opportunity and investable risk.

This gap — between the quality of the work and the visibility of its value — is where promising technologies stall. A prototype that could become a product sits in a laboratory because no one has assembled the evidence of its commercial potential in a form that speaks to the people who fund next stages. A spinout that could exist does not, because the founding researcher has neither the time nor the vocabulary to pitch it convincingly. The university, seeing no external signal of value, assigns none internally.

· · ·

The solution is not to ask scientists to become marketers. It is to give them the equivalent of what every serious commercial innovator already has: a partner who turns the work into a story the right audiences can act on.

What researchers with commercialisable discoveries need is an agent — in the truest sense of that word — who can take their technology and build the investor-ready narrative around it: the market context, the competitive landscape, the evidence of traction, the vision of what comes next. Someone who understands the science well enough to represent it faithfully, and understands the commercial world well enough to make it land. Not a consultant who produces a generic report, but a communication partner who makes the university finally see the value in what is already there — and helps the researcher receive the recognition that the work has long since earned.

What is missing is the infrastructure to make their worth visible — not just to investors, but to the academic structures that still hold researchers' careers in their hands. Until that infrastructure exists, the scientist who builds something genuinely useful will keep being judged by how many papers she filed while doing it.